Theranos
Theranos Fraudulent Blood Testing Technology
Estimated impact: $9B
Theranos claimed to have revolutionized blood testing with proprietary technology that could run hundreds of tests from a single drop of blood. The technology never worked as claimed, yet the company raised over $700 million, reaching a $9 billion valuation as investors and board members deferred to founder Elizabeth Holmes's authority.
Decision context
Whether investors and board members should have demanded independent validation of Theranos's technology claims before investing hundreds of millions of dollars.
The analysis below was produced from the pre-decision document only — no hindsight. This is what the platform would have surfaced if it had been running in 2014-06-15.
“The Edison platform is capable of performing over 200 standard laboratory tests from a single drop of blood drawn from a fingertip. Our proprietary micro-sample technology eliminates the need for traditional venipuncture, making diagnostic testing faster, cheaper, and accessible to millions. We project deployment across 10,000 pharmacy locations within 24 months.”
Source: Elizabeth Holmes, 2014 Theranos Investor Pitch Deck
Red flags detectable at decision time
- No peer-reviewed validation of the Edison device had been published or submitted to any scientific journal
- Board of directors included prominent political figures (Kissinger, Shultz, Mattis) but zero medical device or diagnostics experts
- Walgreens partnership agreement was signed without Walgreens conducting independent testing of the technology
- Internal whistleblower complaints about device accuracy were dismissed and met with legal threats rather than investigation
Cognitive biases the platform would have flagged
Hypothetical analysis
A decision intelligence platform would have flagged the complete absence of peer-reviewed evidence for a medical device claiming 200+ test capabilities as a critical validation gap. The board composition—heavy on political authority figures, devoid of diagnostics expertise—matches the halo effect and authority bias pattern where prestige substitutes for domain competence. The platform would have recommended independent third-party testing as a mandatory prerequisite before any partnership or investment commitment.
What was visible, and when
Every event below was documentable before the outcome was known. The platform looks for signals like these in live memos.
- 2003Holmes drops out of Stanford and founds Real-Time Cures (later Theranos) at age 19.John Carreyrou, "Bad Blood" (2018)
- 2013-09Walgreens begins rollout of Theranos "wellness centers" in Arizona and California stores.Walgreens–Theranos partnership announcement
- 2014-06Forbes cover story pegs Holmes's net worth at $4.5B based on $9B Theranos valuation.Forbes, June 2014
- 2015-02Internal whistleblower Tyler Shultz (grandson of board member George Shultz) files concerns with NY State Department of Health.Tyler Shultz testimony, U.S. v. Holmes
- 2015-10-15John Carreyrou publishes WSJ investigation: Theranos running most tests on third-party Siemens machines, not Edison.Wall Street Journal, October 15 2015
- 2016-01CMS inspection finds deficiencies "jeopardize patient health and safety" at Theranos Newark lab.CMS Form 2567 inspection report
- 2018-03-14SEC charges Theranos, Holmes, and former COO Balwani with "massive fraud."SEC v. Theranos, Case 5:18-cv-01602
- 2022-01-03Jury convicts Holmes on 4 counts of investor fraud.U.S. v. Holmes, N.D. Cal.
- 2022-11-18Holmes sentenced to 135 months in federal prison.U.S. v. Holmes, sentencing order
Primary-source quotes
Stakeholders and positions
Who advocated, who dissented, who was overruled, and who stayed silent — the most reliable single signal of decision-process quality.
Biases present in the decision
Toxic combinations
- Yes Committee
- Echo Chamber
- Golden Child
What a bias-adjusted process would have done
Board requires peer-reviewed validation of Edison technology as a condition of any partnership; Walgreens insists on independent third-party testing before rolling out to stores; early-stage investors (Draper, Oracle's Ellison, DeVos family) condition investment on technical due diligence from a diagnostics-specialist firm; board refreshes to include at least two diagnostics or molecular biology experts alongside political figures.
Theranos is the modern canonical halo-effect/authority-bias failure. Every due-diligence failure traces to the same structural problem: prestigious board, zero domain expertise. The decision to waive technical validation in the presence of "Kissinger and Shultz" is the bias.
Reference class base rates
Across all 135 curated case studies in our library:
Lessons learned
- A prestigious board (Kissinger, Shultz, Mattis) without domain expertise creates authority bias without substantive oversight.
- Confirmation bias led investors to accept curated demos rather than demanding rigorous independent validation.
- When a company aggressively litigates against whistleblowers rather than addressing their claims, it signals systemic deception.
Where the facts come from
- 01John Carreyrou, "Bad Blood: Secrets and Lies in a Silicon Valley Startup"(2018)
- 02SEC v. Theranos, Inc., Elizabeth Holmes, and Ramesh Balwani (Case 5:18-cv-01602)(2018)
- 03U.S. v. Elizabeth A. Holmes (N.D. Cal., verdict & sentencing)(2022)
- 04HBO documentary "The Inventor: Out for Blood in Silicon Valley"(2019)
Source: John Carreyrou, "Bad Blood: Secrets and Lies in a Silicon Valley Startup" (2018); SEC v. Theranos complaint (2018) (News Investigation)
See what we'd flag in your next strategic memo.
Upload a strategic memo or board deck. Get the same hindsight-stripped analysis you just saw for Theranos, on your own high-stakes call, in under 60 seconds.
Or leave your email, we'll run a strategic memo of your choosing and send the readout within a business day.
Ready to audit your own memo right now? Create a free account →